EUVIMEDEUVIMED entdecken
Editorial

Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity

Amalia M Issa

Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)

DOI: 10.1002/cpdd.70051 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.04.2026. Verfasst von Amalia M Issa. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Issa, A. M. (2026). Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70051

Vancouver

Issa AM. Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70051

BibTeX
@article{Issa2026,
  author = {Issa, Amalia M},
  title = {Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cpdd.70051}
}
Kostenlos starten →